Non-Hodgkin Lymphoma (NHL)

A rituximab and lenalidomide combination for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials.

Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.

The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.

The Bruton tyrosine kinase inhibitor was approved in combination with bendamustine and rituximab in previously untreated mantle cell lymphoma (MCL) ineligible for autologous hematopoietic stem cell transplantation and as monotherapy in previously treated MCL.

A pair of studies from The American Society of Hematology (ASH) Annual Meeting & Exposition provides insights into the prognostic utility of geriatric assessment tools and their role in tailoring therapy to improve patient outcomes.

Epcoritamab-bysp showed a 69% objective response rate and 62% complete response rate in older patients with large B-cell lymphoma who were ineligible for anthracycline-based therapy.

This pair of posters presented at the 66th American Society of Hematology Annual Meeting & Exposition provides updates on epcoritamab, currently being investigated in the Epcore NHL-1 trial.

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.

Capivasertib, in combination with venetoclax, produced promising responses in preclinical models of diffuse large B-cell lymphoma (DLBCL).

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events, suggesting long-term safety. The treatment also confirmed magrolimab penetration into the tumor.

A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL).

Danish patients who were diagnosed with certain lymphomas and other B-cell malignancies demonstrated increased antimicrobial use for at least a decade before their diagnosis.

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL).

Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs.

Improvements in multiplex immunofluorescence and spatial analysis have enabled a better understanding of the ways classical Hodgkin lymphoma evades the immune system.

The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.

CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases.

In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).

Better reporting is needed to create better guidelines for tracking infection risk in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, investigators concluded.

Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).

“It's nice to have another option that we can discuss with patients,” said Yasmin H. Karimi, MD, University of Michigan, about epcoritamab’s label expansion for difficult-to-treat relapsed/refractory (R/R) follicular lymphoma.

New Jersey Governor Phil Murphy joined BeiGene CEO John Oyler and about 300 guests to open the facility, located in Hopewell, New Jersey. A version of this article appeared in the August issue of Evidence-Based Oncology.

The social determinants of health (SDOH) that need to be tackled most urgently when it comes to which patients with large B-cell lymphoma (LBCL) do and do not receive chimeric antigen receptor T-cell therapy (CAR T) are age, sex, income, and race/ethnicity.

We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.

A case study describes the disparate factors that played into the chemotherapy and other treatment decisions made by a team in Japan when addressing their patient’s primary mediastinal large B-cell lymphoma (PMBCL).